Chronic Renal Insufficiency Clinical Trial
Official title:
Can the Peritoneal Cavity be a Source of Regulatory B Cells to Treat Auto-immune Disease?
NCT number | NCT03189316 |
Other study ID # | 9828 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | June 6, 2017 |
Est. completion date | December 13, 2017 |
Verified date | June 2018 |
Source | University Hospital, Montpellier |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Some subsets of lymphocytes are able to inhibit immune response and thus, could be used to control auto-immune diseases and transplant reject. In mice, the main source of those anti-inflammatory lymphocytes is the peritoneal cavity. No data are available in human. This study aims at exploring the presence of those anti-inflammatory lymphocytes in human peritoneal cavity and at determine how to expand those cells.
Status | Terminated |
Enrollment | 10 |
Est. completion date | December 13, 2017 |
Est. primary completion date | December 13, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion criteria: - woman over 18 year old undergoing exploration of ovarian cysts by coelioscopy - patient with chronic renal insufficiency undergoing peritoneal dialysis - informed consent obtained Exclusion criteria: - pregnancy or breast-feeding - non affiliation to health care insurance - treatment with corticosteroids over 15 mg/day - treatment with rituximab |
Country | Name | City | State |
---|---|---|---|
France | CHU montpellier - department of rheumatology | Montpellier |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier | Centre National de la Recherche Scientifique, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | relative percentage of regulatory B cells among B cells in peritoneal cavity compared to peripheral blood | Comparison of Breg cell in peritoneal cavity to Breg cell in peripheral blood B | up to 48 hour |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00968877 -
Vitamin D and Chronic Renal Insufficiency
|
Phase 3 | |
Terminated |
NCT00701714 -
Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
|
Phase 3 | |
Completed |
NCT00998972 -
N-acetyl-cysteine (NAC) and Kidney Graft Function
|
Phase 3 | |
Completed |
NCT00716573 -
Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure
|
Phase 4 | |
Recruiting |
NCT04334707 -
Kidney Precision Medicine Project
|
||
Completed |
NCT02203084 -
Social Determinants in Chronic Disease in British Columbia
|
N/A | |
Recruiting |
NCT02147782 -
Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency
|
||
Completed |
NCT01029002 -
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT00742716 -
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT00095056 -
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
|
Phase 3 | |
Completed |
NCT00223548 -
MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application
|
Phase 2 | |
Completed |
NCT01574157 -
Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.
|
N/A | |
Active, not recruiting |
NCT02751099 -
Bone and Cardiovascular Disease After Kidney Transplant
|
||
Recruiting |
NCT02002585 -
Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT01252810 -
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
|
Phase 2 | |
Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
Completed |
NCT00792857 -
Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
|
Phase 1 | |
Completed |
NCT00888069 -
Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects
|
Phase 1 | |
Completed |
NCT00369733 -
STAAR-3 Clinical Study
|
Phase 4 | |
Recruiting |
NCT06362759 -
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
|
Phase 2 |